Madrigal | search
Click here to view Madrigal news from 60+ newspapers.
Bookmark or Share- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full ...About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist ...
- Madrigal Pharmaceuticals Reports Preliminary 2024 Net Sales ... - NasdaqMadrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 ...
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full ...About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist ...
- Why Madrigal Pharmaceuticals Stock Is Sinking TodayMadrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers ...
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full ...Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2023 ...
More
